SM5-1-conjugated PLA nanoparticles loaded with 5-fluorouracil for targeted hepatocellular carcinoma imaging and therapy.

[1]  Jie Tian,et al.  Novel registration for microcomputed tomography and bioluminescence imaging based on iterated optimal projection , 2013, Journal of biomedical optics.

[2]  Paul Steinbach,et al.  Real-time in vivo molecular detection of primary tumors and metastases with ratiometric activatable cell-penetrating peptides. , 2013, Cancer research.

[3]  A. Covey,et al.  Recent progress in understanding, diagnosing, and treating hepatocellular carcinoma , 2012, CA: a cancer journal for clinicians.

[4]  A. Jemal,et al.  Cancer statistics, 2012 , 2012, CA: a cancer journal for clinicians.

[5]  Xin Yang,et al.  Dual-Modality Monitoring of Tumor Response to Cyclophosphamide Therapy in Mice with Bioluminescence Imaging and Small-Animal Positron Emission Tomography , 2011, Molecular imaging.

[6]  S. Singh,et al.  Functionalized Gold Nanoparticles and Their Biomedical Applications , 2011, Nanomaterials.

[7]  D. Dong,et al.  Early detection of liver cancer based on bioluminescence tomography. , 2011, Applied optics.

[8]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[9]  V. Prasad,et al.  Molecular Imaging of HER2-Expressing Malignant Tumors in Breast Cancer Patients Using Synthetic 111In- or 68Ga-Labeled Affibody Molecules , 2010, Journal of Nuclear Medicine.

[10]  Jie Tian,et al.  A trust region method in adaptive finite element framework for bioluminescence tomography. , 2010, Optics express.

[11]  Michael Vieth,et al.  In vivo molecular imaging of colorectal cancer with confocal endomicroscopy by targeting epidermal growth factor receptor. , 2010, Gastroenterology.

[12]  Xin Tong,et al.  Decreased TIP30 expression promotes tumor metastasis in lung cancer. , 2009, The American journal of pathology.

[13]  Weizhu Qian,et al.  Treatment of hepatocellular carcinoma in mice with PE38KDEL type I mutant-loaded poly(lactic-co-glycolic acid) nanoparticles conjugated with humanized SM5-1 F(ab′) fragments , 2008, Molecular Cancer Therapeutics.

[14]  Xin Tong,et al.  Down-regulation of osteopontin suppresses growth and metastasis of hepatocellular carcinoma via induction of apoptosis. , 2008, Gastroenterology.

[15]  Ning Zhang,et al.  5-Fluorouracil: Mechanisms of Resistance and Reversal Strategies , 2008, Molecules.

[16]  W. Cong,et al.  Thirty‐kilodalton Tat‐interacting protein suppresses tumor metastasis by inhibition of osteopontin transcription in human hepatocellular carcinoma , 2008, Hepatology.

[17]  J. Willmann,et al.  Molecular imaging in drug development , 2008, Nature Reviews Drug Discovery.

[18]  U. Hofmann,et al.  Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  R. Weissleder,et al.  Imaging in the era of molecular oncology , 2008, Nature.

[20]  D. Burgess,et al.  A novel in vitro release method for submicron-sized dispersed systems , 1999, AAPS PharmSci.

[21]  Z. Guan,et al.  Pharmacokinetic characteristics and anticancer effects of 5-Fluorouracil loaded nanoparticles , 2008, BMC Cancer.

[22]  Jing Ma,et al.  A chimeric SM5-1 antibody inhibits hepatocellular carcinoma cell growth and induces caspase-dependent apoptosis. , 2007, Cancer letters.

[23]  Jianhua Hu,et al.  Nanoparticles based on the complex of chitosan and polyaspartic acid sodium salt: preparation, characterization and the use for 5-fluorouracil delivery. , 2007, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[24]  David Piwnica-Worms,et al.  Current state of imaging protein-protein interactions in vivo with genetically encoded reporters. , 2007, Annual review of biomedical engineering.

[25]  S. Zou,et al.  Effect of targeted magnetic nanoparticles containing 5-FU on expression of bcl-2, bax and caspase 3 in nude mice with transplanted human liver cancer. , 2007, World journal of gastroenterology.

[26]  Weizhu Qian,et al.  Construction and characterization of a high-affinity humanized SM5-1 monoclonal antibody. , 2007, Biochemical and biophysical research communications.

[27]  Chitra Subramanian,et al.  Imaging protein interactions with bioluminescence resonance energy transfer (BRET) in plant and mammalian cells and tissues , 2007, Proceedings of the National Academy of Sciences.

[28]  M. Schweiger,et al.  Three-dimensional in vivo fluorescence diffuse optical tomography of breast cancer in humans. , 2007, Optics express.

[29]  Hao Wang,et al.  Treatment of hepatocellular carcinoma in a mouse xenograft model with an immunotoxin which is engineered to eliminate vascular leak syndrome , 2007, Cancer Immunology, Immunotherapy.

[30]  H. Ju,et al.  A bio-inspired support of gold nanoparticles-chitosan nanocomposites gel for immobilization and electrochemical study of K562 leukemia cells. , 2007, Biomacromolecules.

[31]  R. Pehrson,et al.  Synthetic affibody molecules: a novel class of affinity ligands for molecular imaging of HER2-expressing malignant tumors. , 2007, Cancer research.

[32]  Sanjiv S Gambhir,et al.  Reporter gene imaging of protein-protein interactions in living subjects. , 2007, Current opinion in biotechnology.

[33]  S. Michnick,et al.  A highly sensitive protein-protein interaction assay based on Gaussia luciferase , 2006, Nature Methods.

[34]  Sanjiv S. Gambhir,et al.  How molecular imaging is speeding up antiangiogenic drug development , 2006, Molecular Cancer Therapeutics.

[35]  Jie Tian,et al.  A multilevel adaptive finite element algorithm for bioluminescence tomography. , 2006, Optics express.

[36]  R. Weissleder.  Molecular Imaging in Cancer , 2006, Science.

[37]  Wenxiang Cong,et al.  A born-type approximation method for bioluminescence tomography. , 2006, Medical physics.

[38]  Asuman Bozkir,et al.  Formulation and investigation of 5-FU nanoparticles with factorial design-based studies. , 2005, Farmaco.

[39]  Geoffrey McLennan,et al.  Practical reconstruction method for bioluminescence tomography. , 2005, Optics express.

[40]  David Grimes,et al.  Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  E. Aboagye,et al.  Early detection of tumor response to chemotherapy by 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography: the effect of cisplatin on a fibrosarcoma tumor model in vivo. , 2005, Cancer research.

[42]  G. Griffiths,et al.  Development of humanized antibodies as cancer therapeutics. , 2005, Methods.

[43]  G. Tortora,et al.  Monoclonal antibodies targeting the epidermal growth factor receptor. , 2005, Current drug targets.

[44]  L. Emens.  Trastuzumab: Targeted Therapy for the Management of HER-2/neu-Overexpressing Metastatic Breast Cancer , 2005, American journal of therapeutics.

[45]  Vasilis Ntziachristos,et al.  Looking and listening to light: the evolution of whole-body photonic imaging , 2005, Nature Biotechnology.

[46]  S. Fulda,et al.  Targeting apoptosis pathways in cancer therapy. , 2004, Current cancer drug targets.

[47]  L. Brannon-Peppas,et al.  Nanoparticle and targeted systems for cancer therapy. , 2004, Advanced drug delivery reviews.

[48]  H. Piwnica-Worms,et al.  Kinetics of regulated protein-protein interactions revealed with firefly luciferase complementation imaging in cells and living animals. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[49]  S. Feng,et al.  Methoxy poly(ethylene glycol)-poly(lactide) (MPEG-PLA) nanoparticles for controlled delivery of anticancer drugs. , 2004, Biomaterials.

[50]  M. Alonso,et al.  Stealth PLA-PEG Nanoparticles as Protein Carriers for Nasal Administration , 1998, Pharmaceutical Research.

[51]  Markus Antonietti,et al.  Vesicles and Liposomes: A Self‐Assembly Principle Beyond Lipids , 2003 .

[52]  P. Johnston,et al.  5-Fluorouracil: mechanisms of action and clinical strategies , 2003, Nature Reviews Cancer.

[53]  S S Gambhir,et al.  Monitoring protein-protein interactions using split synthetic renilla luciferase protein-fragment-assisted complementation. , 2003, Analytical chemistry.

[54]  Vasilis Ntziachristos,et al.  Shedding light onto live molecular targets , 2003, Nature Medicine.

[55]  H. Kaş,et al.  5-Fluorouracil encapsulated alginate beads for the treatment of breast cancer. , 2002, International journal of pharmaceutics.

[56]  P. Johnston,et al.  Capecitabine: a novel agent for the treatment of solid tumors , 2001, Anti-cancer drugs.

[57]  Yanjun Liu,et al.  SM5-1: a new monoclonal antibody which is highly sensitive and specific for melanocytic lesions , 2000, Archives of Dermatological Research.

[58]  D. Harding,et al.  Preparation and in-vitro evaluation of poly[N-vinyl-2-pyrrolidone-polyethylene glycol diacrylate]-chitosan interpolymeric pH-responsive hydrogels for oral drug delivery. , 2000, International journal of pharmaceutics.

[59]  S. Groshen,et al.  Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[60]  F. Lévi,et al.  Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[61]  C Vigneron,et al.  Preparation and characterization of protein C-loaded PLA nanoparticles. , 1999, Journal of controlled release : official journal of the Controlled Release Society.

[62]  J. Robert,et al.  Correlation between uracil and dihydrouracil plasma ratio, fluorouracil (5-FU) pharmacokinetic parameters, and tolerance in patients with advanced colorectal cancer: A potential interest for predicting 5-FU toxicity and determining optimal 5-FU dosage. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[63]  Dm Thomas,et al.  5‐FLUOROURACIL: A PHARMACOLOGICAL PARADIGM IN THE USE OF CYTOTOXICS , 1998, Clinical and experimental pharmacology & physiology.

[64]  C. Tournigand,et al.  Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer. , 1997, European journal of cancer.

[65]  M. Schweiger,et al.  The finite element method for the propagation of light in scattering media: boundary and source conditions. , 1995, Medical physics.

[66]  C. Tournigand,et al.  716 Oxaliplatin with high-dose folinic acid and 5-fluorouracil 48 H infusion in pretreated metastatic colorectal cancer (CRC) , 1995 .

[67]  D. Bazile,et al.  Stealth Me.PEG-PLA nanoparticles avoid uptake by the mononuclear phagocytes system. , 1995, Journal of pharmaceutical sciences.

[68]  Simon Benita,et al.  The influence of process parameters on the PLA nanoparticle size distribution, evaluated by means of factorial design , 1995 .

[69]  J. Folkman,et al.  Tumor angiogenesis and metastasis--correlation in invasive breast carcinoma. , 1991, The New England journal of medicine.

[70]  A. Sodhi,et al.  The effect of histidine on the structure and antitumor activity of metal-5-halouracil complexes. , 1989, Journal of inorganic biochemistry.

[71]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.